Abbott has announced results from a study showing patients with moderate to severely active Crohn's disease treated with Humira (adalimumab) were more likely to maintain clinical remission through one year than patients receiving a placebo, regardless of the frequency of the dosing regimen.

Data from CHARM (the Crohn's trial of the fully Human antibody Adalimumab for Remission Maintenance) showed that remission rates were maintained through 56 weeks in patients who demonstrated response to Humira during a four-week open-label induction phase. Clinical remission was measured by a decrease in the Crohn's Disease Activity Index (CDAI). CDAI is a weighted composite score of eight clinical factors that evaluate patient wellness, including daily number of liquid or very soft stools, severity of abdominal pain, level of general well-being and other measures.